F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dasatinib
  • Drug Resistance, Neoplasm*
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Middle Aged
  • Mutation / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Dasatinib